ABSTRACT: UDP and UDP-glucose activate the P2Y 14 receptor (P2Y 14 R) to modulate processes related to inflammation, diabetes, and asthma. A computational pipeline suggested alternatives to naphthalene of a previously reported P2Y 14 R antagonist (3, PPTN) using docking and molecular dynamics simulations on a hP2Y 14 R homology model based on P2Y 12 R structures. By reevaluating the binding of 3 to P2Y 14 R computationally, two alternatives, i.e., alkynyl and triazolyl derivatives, were identified. Improved synthesis of fluorescent antagonist 4 enabled affinity quantification (IC 50 s, nM) using flow cytometry of P2Y 14 Rexpressing CHO cells. p-F 3 C-phenyl-triazole 65 (32) was more potent than a corresponding alkyne 11. Thus, additional triazolyl derivatives were prepared, as guided by docking simulations, with nonpolar aryl substituents favored. Although triazoles were less potent than 3 (6), simpler synthesis facilitated further structural optimization. Additionally, relative P2Y 14 R affinities agreed with predicted binding of alkynyl and triazole analogues. These triazoles, designed through a structure-based approach, can be assessed in disease models.
■ INTRODUCTION
Extracellular uridine-5′-diphosphate (1) and uridine-5′-diphosphoglucose (2, Chart 1) activate the P2Y 14 receptor (P2Y 14 R), a G protein-coupled receptor (GPCR) belonging to the rhodopsin-like δ-branch, to modulate cell functions related to inflammation, diabetes, asthma, and other diseases. 1, 2 This receptor subtype is a member of the P2Y 12 R-like subfamily of nucleotide receptors, which inhibit the production of 3′,5′-cyclic adenosine monophosphate (cAMP) through G i protein. The P2Y 14 R promotes hypersensitivity in microglial cells, 3 the mobility of neutrophils, 4 the release of mediators from mast cells, 5 inflammation in renal intercalated cells, 6 and mixed effects in insulin function. 7, 8 Thus, approaches to novel antagonists of nucleotide signaling at the P2Y 14 R would be desirable for exploration as novel therapeutics. The P2Y 14 R is also present in the CNS, where it suppresses release of matrix metalloproteinase-9 (MMP-9) and tumor necrosis factor (TNF) from astrocytes. 9 Only a limited set of P2Y 14 R antagonists are currently known. Several chemotypes based on naphthoic acid and pyrido [4,3-d] pyrimidine were reported originally in patents to provide potent P2Y 14 R antagonists, which however displayed low oral bioavailability. 10−13 One of those naphthoic acid derivatives, 4-(4-(piperidin-4-yl)-phenyl)-7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid (PPTN, 3), was profiled pharmacologically at the entire family of eight P2YRs and found to display high affinity and selectivity (IC 50 = 0.4 nM at P2Y 14 R and >10 μM at other P2YR subtypes). 14 We demonstrated that the piperidine group of 3 was a suitable site for chemical derivatization and chain extension to prepare high affinity fluorescent probes of the P2Y 14 R. This conclusion was supported by molecular modeling and ligand docking, which showed the piperidine ring facing outward at the surface of the receptor. 15 One such probe, 4, displayed exceptionally high affinity and low nonspecific binding when used as a tracer in a flow cytometric assay of the P2Y 14 R in whole Chinese hamster ovary (CHO) cells expressing the receptor.
Although previous approaches to modeling of P2YRs were subject to high uncertainty, we now have appropriate templates to obtain detailed docking predictions and structural explanations of previously determined structure−activity relationship (SAR) within the P2Y 12 R-like subfamily, e.g., uracil nucleotides binding to the P2Y 14 R. 16 In the present study, a human (h) P2Y 14 R homology model based on recent hP2Y 12 R X-ray structures 17, 18 served as a template to conduct docking and molecular dynamics (MD) simulations. The immediate goal was to suggest bioisosteric alternatives to the hydrophobic and unwieldy naphthalene ring of 3 that would maintain a similar orientation of the piperidine and 4-(trifluoromethyl)-phenyl substituents when bound to the receptor and therefore preserve receptor affinity. We sought to simultaneously reduce the molecular weight and avoid the high lipophilicity of 3 that contributes to its low solubility and difficulty of purification. 13 
■ RESULTS
The macromolecular starting point of our study is a previously obtained hP2Y 14 R MD-refined homology model based on the agonist-bound hP2Y 12 R X-ray structure (PDB ID: 4PXZ). 16−18 The reference antagonist structure 3 (PPTN) has been docked into the model by using an Induced Fit Docking (IFD) protocol (see Methods section), and the complex has been refined by subjecting it to 10 ns of membrane MD simulations. With respect to the starting agonist-bound hP2Y 14 R homology model (Supporting Information, Figure S1A ), 16 the refined structure used in this study (Supporting Information, Figure S1B ) featured a larger binding cavity extending toward the extracellular side. The adaptation of the binding site to the antagonist structure caused a rearrangement of the position of transmembrane domain (TM)2 and TM7 with respect to the TM bundle (Supporting Information, Figure S2A ): in particular, TM7 was pushed outward, whereas the axis of TM2 became slightly bent toward TM3. Moreover, the extension of the binding site region toward the extracellular side reoriented the first and second extracellular loops (ECL1 and ECL2, respectively) away from the TM bundle (Supporting Information, Figure S2B ,C). Notably, Chart 1. Agonist and Antagonist Ligand Probes of the P2Y 14 R a a Endogenous agonists 1 and 2 have functional EC 50 values at the hP2Y 14 R of 160 and 261 nM, respectively. 45 Antagonist 3 is highly potent at the hP2Y 14 R (K B from Schild analysis = 0.434 nM) 14 but suffers from adverse physicochemical properties (highly hydrophobic/amphipathic) that make dissolution and purification difficult. Fluorescent antagonist 4 is highly potent at the hP2Y 14 R (functional K i = 0.080 nM). 15 . Figure 1 . Workflow of the computational pipeline. Selection of naphthalene bioisosteres was guided by a previous study focused on A 3 AR agonists. Between the two proposed alternatives, the triazole analogue resulted as being the most promising according to membrane MD simulations analysis of the ligand−protein complexes as compared with the reference compound. Consequently, a small library of 57 triazole analogues was designed and docked inside the hP2Y 14 R. Poses were selected by visual inspection. The synthesis and experimental validation of the compounds were prioritized according to the overlap between compounds functional groups and protein interaction sites. the differences described above in the MD refined agonist-and antagonist-bound hP2Y 14 R homology models mirror those experimentally observed for the hP2Y 12 R X-ray structures. 17, 18 Therefore, the final hP2Y 14 R MD-refined structure (Supporting Information) has been used as a template for all subsequent docking simulations.
Starting from this refined template, we developed a computational pipeline comprising three subsequent phases ( Figure 1 ): (i) bioisostere search, (ii) compound screening, and (iii) hit selection. The bioisostere search stage envisaged the use of docking runs followed by 30 ns of MD simulations to identify linking groups as suitable replacements of half of the naphthalene ring while preserving the ligand−receptor interactions observed for the reference compound. The selection of the linkers has been mainly guided by the knowledge gained in a previous study that led to the design of highly potent A 3 adenosine receptor (A 3 AR) agonists. 19 Once a new scaffold was found, a small library of hypothetical compounds was screened by means of docking simulations. Pose filtering and hit selection were based upon ligand−receptor complementarity and optimal overlap between ligand functional groups and computed protein interaction sites.
In the first instance, the parent structure 3 was redocked into the MD-refined model. The corresponding pose ( Figure 2A) showed an overall root-mean-square deviation (RMSD) value with respect to the final MD snapshot of 0.42 Å (data not shown). In the predicted binding mode, the ligand resided in the orthosteric binding site in an orientation similar to that previously reported for hP2Y 14 R antagonist probes:
15 the 2-naphthoic acid carboxylate bridged Lys77 2.60 (according to conventional TM numbering 20 ), Lys277 7.35 , and Tyr102 3.33 , while the piperidine group pointed outward with the nitrogen atom establishing a H-bond interaction with the backbone of Gly80 2.63 . The docking pose has been subjected to 30 ns of membrane MD simulation, and the RMSD with respect to the starting structure has been computed ( Figure 2B , magenta line); this analysis served as a confirmation of the docking pose stability as well as a reference to compare newly proposed compounds containing bioisosteres of the naphthalene. During the MD simulation, compound 3 exhibited an average RMSD of 3.76 Å that can be ascribed mainly to motion of the solvent-exposed piperidine ring. As shown in the trajectory visualization (Supporting Information, Video S1), the naphthalene core with its carboxylate group is well anchored in the binding site during the 30 ns time frame by a tight H-bond network established with Lys77 2.60 , Lys277 7.35 , and Tyr102 3.33 . However, the distal piperidine nitrogen suddenly moved apart from the pose predicted by docking and approached the backbone of Ile170 in the second extracellular loop (EL2) through the interplay of water molecules.
The first proposed alternative structure was an alkyne derivative (11, Scheme 1) containing a p-CF 3 -phenyl group, similar to 3. The compound was docked into the MD-refined hP2Y 14 R homology model and then subjected to 30 ns of MD simulations. In the resulting pose ( Figure 2C ), the trifluoromethylphenyl group was buried in a deep hydrophobic pocket, and the carboxylate group interacted with Lys77 2.60 , Tyr102
3.33 , and Lys277 7.35 as in the docking pose of 3 ( Figure 2A ). Although during the MD simulations of the hP2Y 14 −11 complex, the ligand atoms displayed an average RMSD value (3.79 Å) close to the one observed for the reference compound, the corresponding graph suggested that compound 11 was less stable than 3 in the binding pocket ( Figure 2B , orange and magenta lines, respectively). In particular, in the first 15 ns of simulation, compound 11 experienced an increasing deviation from the starting pose, leading to a higher root-mean-square fluctuation (RMSF = 1.52 vs 1.16 Å for compounds 11 and 3, respectively). The trajectory analysis (Supporting Information, Video S2) revealed that, after a few ns, the piperidine ring of derivative 11 moved from the docking pose to establish an H-bond interaction with the backbone of Ile170 EL2 and Gln169 EL2 in a way similar to that observed for the reference compound. On the other hand, after approximately 12 ns, the side chain of Tyr102 3.33 moved to engage the trifluoromethylphenyl group in a T-shaped π−π stacking interaction. This movement caused a weakening of the H-bond network around the carboxylate moiety of 11 that increased the number of water molecules surrounding the group during the trajectory.
On the basis of the analogy observed for the docking poses and trajectory analyses of compound 11 with respect to the reference structure 3, we synthesized 11 using both Sonogashira 21 and Suzuki 22 cross-coupling reactions (Scheme 1). In particular, a Sonogashira coupling reaction of a iodo arene 5b with 4-(trifluoromethyl)phenylacetylene (6) in the presence of tetrakis-(triphenylphosphine)palladium yielded derivative 7. Compound 5b was obtained by esterification of a commercial precursor 5a. The 3-hydroxy group of 7 was then converted to the corresponding aryl triflate 8 using triflic anhydride and pyridine. A Suzuki cross-coupling reaction between 8 and dioxaborolane derivative 9, prepared by conventional Suzuki−Miyaura reaction 23 in the presence of tetrakis(triphenylphosphine)-palladium catalyst, afforded compound 10. Finally, removal of the N-Boc protecting group followed by hydrolysis of the ester provided derivative 11. This route would allow a wide variety of substitutions to be introduced at a late stage in the synthetic sequence because of the commercial availability of numerous arylacetylene derivatives.
On the basis of the suggestion that the replacement of the naphthoic acid core of 3 with an alkynyl group might lead to the loss of an anchoring hydrogen bond with Tyr102 3.33 , other alternatives were considered as well. A similarly versatile synthetic approach could be used for introducing arylacetylene moieties in the form of 1,2,3-triazoles by copper-catalyzed [2 + 3] cycloaddition 24 with an azido group present on the core of the molecule. The corresponding triazole derivative containing a p-CF 3 -phenyl group (65, Scheme 2) was subjected to the same computational protocol described for compound 11 (docking followed by 30 ns of MD simulations). The resulting docking pose ( Figure 2D ) suggested a placement of compound 65 in the binding site similar to that predicted for 3 and 11, which encompassed a tight H-bond network around the carboxylate group with the piperidine ring solvent-exposed. On the other side, a slightly higher placement within the binding site enabled compound 65 to establish an additional π−π stacking interaction with the side chain of His184 5.36 , while the piperidine ring was anchored by an H-bond with the Ile167 EL2 backbone. MD simulations of the hP2Y 14 . The carboxylate group of 65 maintained a stable position, and the water molecules surrounding the carboxylate group of 11 were not observed during the simulation of the hP2Y 14 −65 complex.
On the basis of these favorable predictions, using a strategy similar to Scheme 1, triazolyl derivative 65 and its analogues were synthesized starting from the 3-amino-5-bromobenzoic acid (12) and 4-(4-bromophenyl)piperidin-4-ol (16, Scheme 2). The carboxylic group of 12 was first converted to the methyl ester 13, and then the amine function was protected to give Boc-derivative 14. The palladium-catalyzed condensation of aryl bromide 14 with bis(pinacolato)-diboron under basic conditions afforded dioxaborolane 15. The acid-catalyzed dehydration of 16 yielded alkene 17, which was reduced to provide compound 18. Derivative 19 was obtained by coupling 18 with compound 15 under Suzuki conditions. 22 The conversion of the amino group of 19 to a trifluoroacetamide 20 was accomplished using trifluoroacetic anhydride in the presence of triethylamine. Removing the N-Boc protecting group of 20 gave the amine 21. Compound 21 was converted into aryl azide 22 from an arenediazonium tosylate that was generated in situ and subsequent addition of sodium azide. 25 The protected 1,2,3-triazolyl derivatives 23−63 were synthesized via an azide−alkyne Huisgen cycloaddition ("click Tables 1 and 2 . reaction") involving aryl azide 22, various alkynes, Cu(II)sulfate salt, and sodium ascorbate. 26 One-pot hydrolysis of the trifluoroacetamide and the ester in the presence of KOH yielded compounds 64−104, which were purified by semiprep HPLC and isolated either as acetate or triethylammonium salts.
The synthesis of fluorescent antagonist 4 as previously reported 15 suffered from a low yield in the final click cycloaddition step to link the azide-functionalized fluorophore and the alkyne-functionalized pharmacophore. Given the unusually high affinity of 4 and its low nonspecific character, we explored an alternate synthesis of 4. This was necessary to provide a sufficient supply of fluorescent probe 4 for use in routine assays, which we needed for the new putative antagonists 11 and 64−104. A more efficient route consisted of forming an amide as the ultimate or penultimate step. Thus, the pharmacophore was functionalized with an extended amine through a preformed triazole linker to provide intermediate 113 (Scheme 3A). The coupling of AlexaFluor488 fluorophore 27 and pharmacophore was attempted by two methods, either: (1) condensation of the fluorophore as a 5-carboxylic acid 115 to the ethyl ester-protected derivative 113 of the pharmacophore followed by ester saponification, or (2) by reaction of the fluorophore that was activated in situ as a N-succinimidyl ester 116 with the amino derivative 114, having a deprotected carboxylic acid (Scheme 3B). However, only the second synthetic route provided compound 4 and at the same time improved the reaction yield compared to the previous synthetic method. 15 Furthermore, we explored a different fluorescent antagonist analogue for possible use in screening, e.g., 130 containing a cyanine-5 (Cy5) fluorophore, but this compound was considerably less potent at the hP2Y 14 R in comparison to 4 (Supporting Information).
Alkyne derivative 11 was tested in a functional assay of antagonism of the agonist-induced inhibition of cAMP production in the presence of 30 μM forskolin in Chinese hamster ovary (CHO-K1) cells stably expressing the hP2Y 14 R (P2Y 14 R-CHO cells, using an EC 80 concentration of agonist 2 of 316 nM).
14 Under these conditions, the IC 50 values for 11 was 5690 ± 1440 (n = 3). Thus, this alkyne derivative was shown to be an antagonist with considerably less affinity than reference antagonist 3.
Although the alkyne 11 was not deemed a high priority lead compound because of its moderate potency, the triazoles achieved higher affinity. Compound 65 and the other newly synthesized triazole derivatives were assayed in a flow cytometry competition assay using whole cells (P2Y 14 R-CHO), and fluorescent antagonist ligand 4 (20 nM) as a tracer. Figure 3A shows typical flow cytometry traces in the presence of representative triazole inhibitors at a single concentration. The antagonist affinities of the various analogues were compared by this method, first by screening at a relatively high single concentration of inhibitor (3 μM) to identify the most potent analogues. The reference compound 65 inhibited fluorescent labeling by 92%; thus, it appeared to be a suitable highly potent lead compound for exploring the SAR in this series. Those IC 50 values of triazole analogues inhibiting the fluorescent labeling by 80% or greater were determined in full concentration−response curves, which were sigmoidal, as shown for representative compounds in Figure 3B .
Selection of favored terminal aryl groups in the triazole series, other than 4-F 3 C-Ph (65), was based on predictions arising from the docking of a library of 57 hypothetical triazole derivatives (Supporting Information, Table S1 ), which could be easily synthesized by the same route as for 65. The criteria underlying the hit selection are reported in Table 1 and are based upon ligand−receptor complementarity and overlap of scaffold functional groups with computed receptor interaction sites (Supporting Information, Table S2 ). Initially, selected entries 66−75 were synthesized for testing using the fluorescent hP2Y 14 R assay. On the basis of the SAR determined for the initial set, a second group of P2Y 14 R antagonists 76−104 was prepared (Table 2 ) and evaluated similarly for the ability to inhibit fluorescent binding at the hP2Y 14 R.
The compounds that at 3 μM displayed inhibition of >80% of the fluorescent ligand (4, 20 nM) binding to the P2Y 14 R tended The most potently binding triazole derivative 65 was shown in measurements of cAMP to be an antagonist at the P2Y 14 R expressed in CHO cells, similar to known and potent antagonist 3 ( Figure 3C ). P2Y 14 R agonist 2 (1 μM) was applied in the absence or presence of antagonist 3 (1 μM) or compound 65 (1 μM) to cells stimulated with 30 μM forskolin. As expected, compound 2 significantly decreased forskolin-induced cAMP levels, but in the presence of either compound 3 or 65, P2Y 14 R agonist 2 did not inhibit cAMP accumulation. We also studied the effect of compound 65 on calcium mobilization induced by several other P2YRs. 65 (up to 10 μM) was inactive as either agonist or antagonist at the hP2Y 1 R and hP2Y 6 R expressed in 1321N1 astocytoma cells (Supporting Information, Figure S4 ). Compounds 11, 65 , and 74 were separately evaluated by the Psychoactive Drug Screening Program (PDSP) 28 at various P2YRs and found to be inactive (10 μM) as agonist or antagonist at human P2Y 1 , P2Y 2 , P2Y 4 , and P2Y 11 Rs (calcium transients) expressed in 1321N1 astrocytoma cells and protease-activated receptor (PAR)1 expressed in mouse KOLF cells.
Off-target activities for selected compounds were measured by the PDSP. 28 Compounds 3 and 11 each showed only a few offtarget interactions at <10 μM. At these sites, the measured K i values (μM) of 3 were 6.79 (D 3 dopamine receptor) and 2.75 (δ-opioid receptor), and the K i values (μM) of 11 were 1.46 (σ 1 receptor) and 3.60 (σ 2 receptor). All other receptors, channels, and transporters in the standard diverse screen of the PDSP were not significant (i.e., <50% binding inhibition at 10 μM). A representative triazole derivative (74) showed no off-target interactions, but the trifluoromethyl analogue (65) bound weakly (K i , μm) at H 1 histamine (0.17) and α 2A (1.56) and α 2C (1.32) adrenergic receptors. Thus, only a few off-target interactions were detected in these chemical series.
■ DISCUSSION
The aim of this project was the synthesis of a library of novel triazole-based structures as possible antagonists of the P2Y 14 R having improved physicochemical properties. A triazole moiety was proposed as an alternative bioisosteric replacement for the c All ligands were docked to a 10 ns molecular dynamics refined 3-bound P2Y 14 R homology model. naphthoic acid core of the potent P2Y 14 R antagonist 3. On the basis of the results previously achieved with the same substitutions for A 3 AR agonists, 19 alkyne derivatives and triazole derivatives were considered for components of the core to mimic the favorable interactions present in the naphthoic acid series. By docking to a homology model of the receptor, the envisaged structures were predicted to occupy the same binding site within the P2Y 14 R as 3, maintaining a similar orientation of the (11); thus, the triazoles were explored in detail.
The synthetic route to the triazole series was versatile to allow the introduction of a wide range of functional groups on a terminal aryl substituent late in the synthesis. Both Suzuki and click cycloaddition reactions were applied sequentially to a benzoic ester moiety. The triazole derivatives were prepared by a late-stage diversification strategy, introducing the 1,2,3-triazole moiety at the end of the synthetic sequence by a copper-catalyzed [2 + 3] cycloaddition between an azide moiety and various arylacetylene derivatives. The choice of arylacetylene derivatives was initially guided by docking and MD studies. The overall yield from aniline 12 to protected azide 22 was 15%, with the last two steps (click reaction and deprotection) of variable, but usually high yield. One unexpected result was the hydrolysis of the 3-cyanophenyl group during the last deprotection step to a 3-carboxyphenyl group (92).
These new compounds were assayed in a convenient flow cytometric fluorescence competition assay with our previously reported antagonist probe 4 in P2Y 14 R-CHO cells, confirming the general docking predictions. Moreover, the expanded SAR exploration (Table 2 ) provided greater insight. The terminal aryl group attached to the triazole required hydrophobic substitution for high affinity, as the unsubstituted phenyl analogue (64) was weak in P2Y 14 R binding. The general preference for substitution of a phenyl ring at this position was p-> m-≥ o-, as evidenced with the methoxy analogues (81 > 68 ≥ 83) and the fluoro analogues (87 > 88 ≈ 89). Similarly, there was a preference for pover m-substitution in trifluoromethyl (65 > 80) and trifluoromethoxy (84 > 85) analogues. Thus, there is a hydrophobic pocket that tolerates considerable steric bulk, e.g., the 4-tert-butyl analogue (79), in this region of the receptor, as predicted in ligand docking to the P2Y 14 R homology model. However, introducing polar groups to form predicted H-bonding interactions with specific groups surrounding this aryl ring failed to enhance affinity. This trend could be explained by the observation that a residue side chain (Ser187 5.39 ) that was predicted in the docking simulation to form H-bonds with the ligand polar groups was not available for ligand interaction when analyzed in the dynamic context of the membrane-embedded solvated receptor (data not shown). The most potent compounds, with IC 50 values ranging from 32 to 131 nM, had substituents: 4-CF 3 -ϕ 65 > 4-n-propyl-ϕ 77 > 5-Br-thienyl 75 > 4-Br-ϕ 71, 4-n-pentyloxy-ϕ 82, and 4-CF 3 O-ϕ 84. Substitution of the 4-CF 3 group of 65 with 4-CH 3 in 76 considerably lowered the affinity 7-fold (IC 50 237 nM). These affinities were not as potent as reference compound 4 (IC 50 6.0 nM) in the same assay. The lead molecule 3 is a highly selective antagonist of the P2Y 14 R; 14 although selectivity of these antagonists with respect to P2Y 12 R and P2Y 13 R remains to be determined, several derivatives were shown to be inactive at all P2Y 1 -like receptors.
The physicochemical properties of the triazole derivatives remain to be determined experimentally. However, an online tool for calculating small-molecule pharmacokinetic and toxicity properties predicted some advantage; 3 (2.7 μM solubility predicted) would be 100% bound to human plasma protein and 65 (6.9 μM solubility predicted) would be 1.5% unbound. 29 The triazole ring benefited from increased polarity and additional Hbond accepting groups compared to the naphthalene core of 3. The cLogP of 3 is 5.65, which is more hydrophobic than the optimal range of ∼2−4, while the corresponding triazole derivative 65 had a cLogP of 4.59. The halogen substitution of a potent 3,4-difluorophenyl analogue 90 might impede potential oxidation by CYP450 enzymes in the liver.
■ CONCLUSION
In conclusion, we have used structural insights to discover a new scaffold 3-(4-aryl-1H-1,2,3-triazol-1-yl)-biphenyl) for P2Y 14 R antagonists. The high affinity among members of this chemical series of triazole derivatives provides new tools to aid in our understanding of P2Y 14 R pharmacology and potentially could lead to clinically useful drug candidates for inflammatory, endocrine, and other conditions.
■ EXPERIMENTAL SECTION
Chemical Synthesis. Reagents and Instrumentation. The proton and carbon nuclear magnetic resonance spectra were recorded using Bruker 400 MHz, Bruker 500, or Bruker 600 NMR spectrometer. Purification of final compounds was performed by preparative HPLC (column: Luna 5 μm C18 (2) min, then triethyammonium phosphate monobasic solution−CH 3 CN from 0:100 to 90:10 in 5 min with a flow rate of 1 mL/min. Peaks were detected by UV absorption (254 nm) using a diode array detector. All derivatives tested for biological activity showed >95% purity in the HPLC system. Analytical thin-layer chromatography was carried out on Sigma-Aldrich TLC plates, and compounds were visualized with UV light at 254 nm. Silica gel flash chromatography was performed using 230−400 mesh silica gel. Unless noted otherwise, reagents and solvents were purchased from Sigma-Aldrich (St. Louis, MO). Compound 3 was synthesized as reported.
14 Low-resolution mass spectrometry was performed with a JEOL SX102 spectrometer with 6 kV Xe atoms following desorption from a glycerol matrix or on an Agilent LC/MS 1100 MSD, with a Waters (Milford, MA) Atlantis C18 column. High- resolution mass spectroscopic (HRMS) measurements were performed on a proteomics optimized Q-TOF-2 (Micromass-Waters) using external calibration with polyalanine. cLogP was calculated using ChemDraw Professional (PerkinElmer, Boston, MA, v. 15.0). (4) . To a solution of AlexaFluor 488 115 (4.44 mg, 7.08 μmol) and N,N-diisopropylethylamine (1.34 μL, 7.72 μmol) in dry DMF (400 μL), TSTU (2.42 mg, 7.72 μmol) was added at 0°C. The resulting mixture was allowed to warm up at rt and stirred for 2−3 h. Then, a solution of 114 (4.5 mg, 6.44 μmol) and N,Ndiisopropylethylamine (1.30 μL, 7.08 μmol) in dry DMF (300 μL) was added, and the reaction was stirred overnight at rt. After removal of the solvent, the residue was purified by preparative HPLC (method A, R t = 24.9 min). The product 4 was obtained as an orange solid after lyophilization (0.8 mg, 10% (11) . Lithium hydroxide (aqueous 0.5M, 70 μL, 25 μmol) was added to a solution of 10 (13 mg, 23 μmol) in methanol (0.2 mL), and the mixture was heated at reflux for 1.5 h. During this time, 10 was completely consumed. The mixture was allowed to cool to 23°C and acidified with hydrochloric acid (1 M) until pH 1. The acidified mixture was stirred for additional 2 h before solvents were removed under reduced pressure. The residue was subjected to column chromatography (silica gel), eluting with chloroform/ methanol/acetic acid 100/10/1 (v/v) mixture. Hydrochloric acid (1 M) was added to fractions containing the product, and the solvent was removed under reduced pressure to provide the desired product 11 as a hydrochloride salt (3.1 mg, 28% General Procedure A: Click Cycloaddition Reaction. To a solution of aryl azide (22, 1 equiv) and aryl alkyne (1.5 equiv) in 2 mL of THF:water (1:1), sodium ascorbate (freshly prepared 1 M aqueous solution) and CuSO 4 (0.5 equiv) were sequentially added. The resulting reaction was vigorously stirred for 12 h at rt. The reaction mixture was then concentrated in vacuo and purified by flash chromatography (hexane:ethyl acetate = 6:4). Hex-5-yn-1-yl 4-Methylbenzenesulfonate (106). To a solution of hex-5-yn-1-ol 105 (0.84 mL, 7.64 mmol), triethylamine (1.28 mL, 9.17 mmol), and 4-(dimethylamino)pyridine (20 mg, 0.15 mmol) in CH 2 Cl 2 (25 mL) at 0°C was added p-toluenesulfonyl chloride (1.53 g, 8.02 mmol) in three portions. The reaction mixture was brought to rt. and stirred for 15 h. Aqueous NaOH (1 N, 15 mL) was added, and the mixture was vigorously stirred for 15 min at rt. The aqueous phase was extracted with CH 2 Cl 2 . The combined organic fractions were washed with water, followed by brine, and then dried over Na 2 SO 4 , filtered, and concentrated in vacuo to give the title compound (1.68 g, 88%) as a yellowish oil. 6-Bromohex-1-yne (107). LiBr (1.7 g, 19.6 mmol) was added to a stirred solution of 106 (1.64 g, 6.52 mmol) in dry DMF (20 mL). After the exothermic reaction, the mixture was stirred at room temperature for 24 h. Then water (25 mL) was added and the aqueous phase extracted with Et 2 O (3 × 25 mL). The collected organic fractions were dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by flash chromatography using as eluent hexane:ethyl acetate (5:1) to afford a colorless oil (0.86 g, 82%). 6-Bromohexan-1-amine Hydrochloride (109). 6-Aminohexanol 108 (0.5 g, 4.27 mmol) was slowly added to a stirring 48% HBr solution (5.1 mL) at 0°C, and the resulting mixture was stirred at 80°C for 20 h. The mixture was neutralized by adding 2N NaOH (20 mL) and extracted with ethyl acatate (3 × 20 mL). The combined organic fractions were washed with water (50 mL) followed by brine (50 mL) and then dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The obtained viscous oil was dissolved in 4 M HCl solution in dioxane to give a sticky solid that was washed with Et 2 O and then filtered to afford a yellowish solid (0.55 g, 61%). 6-Azidohexan-1-amine (110). To a solution of 109 (0.55 g, 2.54 mmol) in water (25 mL), NaN 3 (0.49 g, 7.69 mmol) was added, and the resulting mixture was heated at 100°C for 12 h. After cooling, 37% ammonia solution was added until a basic pH was reached, and the aqueous phase was extracted with Et 2 O (3 × 20 mL). The organic fractions were collected, dried over Na 2 SO 4 , and filtered, and the solvent removed under vacuum to give a yellow oil (0.29 g, 80%). 1 Compound 107 (0.06 g, 0.6 mmol) was subsequently added, and the reaction mixture was first stirred at rt for 2h and then at 50°C for 2.5 h. After cooling down at rt, saturated NaHCO 3 solution (15 mL) was added, and the aqueous phase extracted with ethyl acetate (3 × 20 mL). The collected organic fractions were dried over Na 2 SO 4 , filtered, and the solvent removed in vacuo. The residue was purified by chromatography using as eluent CH 2 Fluorescent Ligand Binding. Fluorescent ligand binding experiments were performed using FCM for all the final triazole derivatives. An initial experiment involved screening of the compounds at a single concentration (3 μM) to determine the percentage inhibition, followed by a full concentration−response curve for the more potent compounds.
For FCM binding experiments in hP2Y 14 R-CHO cells using 4 as fluorescent tracer, 15 CHO cells expressing hP2Y 14 Rs were grown in 12-well plates and used for the assay when the cells were 80% confluent. CHO cells were incubated with a test compound (nonfluorescent antagonist) for 30 min, followed by continued incubation for 30 min after the addition of 20 nM of fluorescent antagonist 4. After the incubation, the cells were prepared for FCM analysis as described below. Briefly, cells were washed 3 times with ice-cold PBS and detached with 0.2% EDTA, which was neutralized with media after 5 min incubation at 37°C. Cell suspensions were transferred to polystyrene round-bottom BD Falcon tubes (BD, Franklin Lakes, NJ), and centrifuged twice at 400g for 5 min. Cells were then suspended in PBS and proceeded to FCM using a FACSCalibur flow cytometer (BD, Franklin Lakes, NJ), with a 635 nm laser. MFIs were recorded in FL-1 channel in log mode. All data were analyzed by nonlinear least-squares analysis, and K i values were calculated using Prism (GraphPad Software, San Diego, CA) for all assays.
To quantify the number of receptor-bound ligands, we used quantitative fluorescence calibration. To convert measured fluorescence intensity (MFI) values into molecules of equivalent soluble fluorochrome (MESF) values, we used Quantum Alexa fluor 488 MESF calibration beads and QuickCal program v. 2.3 (Bangs Laboratories, Inc., Fishers, IN) according to the instructions of the manufacturer. The detailed procedure is explained in the Supporting Information ( Figure S3 ).
Compounds 79, 82, 95, and 101 displayed low solubility in DMSO, and therefore their 5 mM DMSO-solutions were heated to 50°C for 5 min prior to the dilution step. To confirm the physicochemical stability of the derivatives, 1 H NMR spectra were taken before and after heating, and no change in the 1 H NMR was observed. Quantification of cAMP Accumulation. cAMP accumulation in cells was quantified by competitive enzyme-linked immunoassay. Cells were plated in 12-well plates 24 h before the assay, and 30 min before the assay the cells were washed with PBS and the medium was changed to 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-buffered serum-free DMEM. The assays were performed in the presence of 10 μM rolipram and were initiated by the addition of 30 μM forskolin, agonist and/or antagonists.
14 Incubation was for 15 min at 37°C and were terminated by washing the cells twice with ice-cold PBS, and the cells were lysed using 100 μL of cell lysis buffer (Cell Signaling, Danvers, MA). Then 50 μL of the cell lysate were used for the quantification of cAMP using a Cyclic AMP XP assay kit (Cell Signaling, Danvers, MA) following manufacturer's instructions.
Molecular Modeling. Homology Model Refinement. Compound 3 was built using Maestro and prepared with the Ligprep module 31 using the OPLS-2005 force field. 32 The ligand was docked to the previously obtained UDP-bound MD-refined hP2Y 14 R homology model 16 by means of the Induced Fit Docking (IFD) procedure based on Glide search algorithm and SP scoring function. 33 In particular, a Glide grid was positioned on the centroid of residues located within 5 Å from the previously identified cavity. 16 The Glide grid was built using an inner box of 10 Å × 10 Å × 10 Å and an outer box that extended 20 Å in each direction around the inner box. The ligand was docked rigidly, and side chains within 5 Å of the ligand were refined. The top ranked docking pose was then subjected to 10 ns of MD simulations and the final trajectory snapshot of the receptor used as a template to redock compound 3 and to dock compounds 11 and 65 along with its structural analogues.
Docking of Compounds 3, 11, and 65. Ligands were built using Maestro and prepared using the Ligprep module 31 and OPLS_2005 force field. 32 Molecular docking of ligands to the 3-bound hP2Y 14 R MDrefined model was performed by means of the Glide software package 34 from the Schrodinger suite, using the XP scoring function. 35 The binding site was centered on the ligand barycenter and a Glide grid was computed (inner box side = 10 Å; outer box side = 30 Å). The top ranked docking poses for each ligand were subjected to 30 ns of membrane MD simulations.
Molecular Dynamics. The setup of the MD simulation was performed as previously described. 16 In brief, the hP2Y 14 R homology model was uploaded to the "Orientations of Proteins in Membranes (OPM)" server 36 and a suggested orientation was provided based on the 2MeSADP-bound hP2Y 12 R orientation (PDB: 4PXZ). 18 The model was then positioned in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipid bilayer (70 Å × 70 Å) generated by a grid-based method using the VMD 37 Membrane Plugin tool, and overlapping lipids within 0.6 Å were removed upon combining the protein and the membrane system. Each protein−membrane system was then solvated with TIP3P water using the Solvate 1.0 VMD 37 Plugin tool and neutralized by 0.154 M Na + /Cl − counterions. High-performance computational capabilities of the Biowulf Linux GPU cluster at the National Institutes of Health, Bethesda, MD (http:// biowulf.nih.gov) were exploited to run MD simulations with periodic boundary conditions using the Nanoscale Molecular Dynamics (NAMD) software package 38 and the CHARMM36 Force Field. 39, 40 The ligands were parametrized by analogy using the ParamChem service (1.0.0) and implementing the CHARMM General Force Field for organic molecules (3.0.1). 41, 42 A 10000-step conjugate gradient minimization was initially performed to minimize steric clashes. The protein and ligand atoms were kept fixed during an initial 8 ns equilibration of the lipid and water molecules. Atom constraints were then removed, and the entire system was allowed to equilibrate. The temperature was maintained at 300 K using a Langevin thermostat with a damping constant of 3 ps −1 . The pressure was maintained at 1 atm using a Berendsen barostat. An integration time step of 1 fs was used, while hydrogen−oxygen bond lengths and hydrogen−hydrogen angles in water molecules were constrained using the SHAKE algorithm. 43 VMD 1.9 37 was used for trajectory analysis and movie making. Each structure was simulated for 30 ns without constraints. RMSD plots for ligand atoms during the 30 ns trajectories were used to compare relative ligand stability in the binding pocket during the simulation. Docking of Triazole Analogues. A library of 57 triazole compounds was designed and screened using the 3-refined P2Y 14 model as receptor template. The binding pose of 3 was set as a constraint for the docking, including exposure of the positively charged piperidine ring toward the solvent and 2-naphthoic acid carbonyl interactions with Lys77 2.60 and Lys277 7.35 . Molecular docking of ligands to the hP2Y 14 R MD-refined model was performed by means of the Glide package, 34 using the SP scoring function. The ligand binding site was defined as abovedescribed. Protein interaction sites were calculated by means of the SiteMap package 44 as implemented in the Schrodinger suite on the apo form of the hP2Y 14 R MD-refined model by generating at least 15 points per site with the OPLS_2005 force field. 32 The top ranked site was used to select the compounds according to optimal overlap between hydrophobic and hydrogen bond donor/acceptor protein sites and ligand functional groups evaluated by visual inspection. 
